1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Network-Driven Discovery – The Solution To Pharma's Productivity Challenge?

 
• By Lucie Ellis-Taitt

Ray Barlow, CEO of e-Therapeutics, talks to Scrip on the sidelines of the BIO-Europe partnering conference in Berlin, Germany, about network-driven discovery and its use by today's innovative pharma sector.

Video interview

CEO of e-Therapeutics PLC, Ray Barlow, talks about working backwards to solve drug discovery and development problems, starting with the end target in mind and then thinking about how to apply new technologies to reach the bull's eye.

E-therapeutics' technology works by combining biological expertise and a powerful computer-based platform to create and analyze network models of disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

India’s R&D Funding Push: Catalytic To De-Risking Early Innovation?

 
• By Anju Ghangurde

India rolls out amended R&D financial assistance plan targeting certain ‘priority areas’ and calls for proposals from industry and startups. While the corpus is modest, the scheme hopes to enable the ‘Innovate in India’ ecosystem and includes a co-funding provision.

Attractiveness of Cell Therapy In The Spotlight With Limited Interest In Galapagos Unit

 
• By Kevin Grogan

Non-binding offers have come mostly from groups of financial investors rather than biopharma players.

Novo Holdings Invests In Pharma R&D’s Potential Quantum Leap

 
• By Andrew McConaghie

Quantum computing is seen as key to future improvements in biopharma R&D productivity, and Novo Holding believes 55 North can be a leading venture funder in the field.

Spanish VC Asabys Sees Bright Future For Biotech

 
• By Kevin Grogan

The firm aims to become one of the largest life science general partners in southern Europe.

More from Business

Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 
• By Alaric DeArment

The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Stock Watch: Baby Steps In Most Favored Nation Drug Pricing

 
• By Andy Smith

Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.